FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)

DRUG2 trials

Sponsors

ITM Solucin GmbH, University of Campania Luigi Vanvitelli

Conditions

Metastatic Colorectal Cancer (mCRC)Neuroendocrine Tumors

Phase 3

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Active, not recruitingNCT04919226

ITM Solucin GmbHNeuroendocrine Tumors

Start: 2021-12-21End: 2027-09-30Updated: 2025-09-10

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

RecruitingNCT07389265

University of Campania Luigi VanvitelliMetastatic Colorectal Cancer (mCRC)

Start: 2025-10-01End: 2030-10-01Target: 480Updated: 2026-02-05

Related Papers

Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.

Journal of Clinical Oncology2023-02-011 citations

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.

2022-04-136 citations

Pivotal phase III COMPOSE trial will compare <sup>177</sup>Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Journal of Clinical Oncology2022-01-1924 citations